Drugs.com - Clinical Trials Clinical trial news from Drugs.com. Comprehensive, up-to-date drug news for consumers and healthcare professionals.
- Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activityon November 19, 2024 at 10:11 pm
BRUSSELS, Belgium and CAMBRIDGE, Mass. – November 19, 2024 – UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel...
- Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpointson November 19, 2024 at 10:11 pm
RAHWAY, N.J. November 19, 2024 -- Merck, known as MSD outside of the United States and Canada, today announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial is evaluating the noninferiority of subcutaneous...
- Cardiovascular Researchers Dramatically Reduce Size and Severity of Stroke Using Antidiabetic Drug in Preclinical Modelson November 19, 2024 at 9:11 pm
PASADENA, Calif., Nov. 19, 2024. Huntington Medical Research Institutes (HMRI), a pioneer in scientific research with a track record of groundbreaking discoveries, announced promising breakthroughs in the treatment of stroke at the American Heart...
- Linerixibat Shows Positive Phase III Results in Cholestatic Pruritus in Primary Biliary Cholangitis (PBC)on November 19, 2024 at 2:11 am
19 November 2024 -- GSK plc (LSE/NYSE: GSK) today announced positive headline results of GLISTEN, the ongoing global phase III clinical trial evaluating linerixibat, an investigational targeted inhibitor of the ileal bile acid transporter (IBAT), in...
- Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Monthson November 18, 2024 at 10:11 pm
PALO ALTO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, presented positive initial...
- Muvalaplin Lowered Lipoprotein(a) Levels in Adults with High Risk for Cardiovascular Events by up to 85% at Highest Tested Doseon November 18, 2024 at 10:11 pm
INDIANAPOLIS, Nov. 18, 2024. Eli Lilly and Company today announced positive Phase 2 results for muvalaplin, an investigational once-daily, orally administered selective inhibitor of lipoprotein(a) [Lp(a)], a genetically inherited risk factor for...
- Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiranon November 18, 2024 at 7:11 pm
PASADENA, Calif.–(BUSINESS WIRE)–Nov. 18, 2024– Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced new results from the Phase 3 PALISADE study and the open-label extension from the Phase 2 MUIR and SHASTA-2 studies of...
- Icotrokinra Delivered an Industry-Leading Combination of Significant Skin Clearance with Demonstrated Tolerability in a Once Daily Pill in Phase 3 Topline Resultson November 18, 2024 at 12:11 am
SPRING HOUSE, Pa. (November 18, 2024) – Johnson & Johnson (NYSE: JNJ) today announced positive topline results from ICONIC-LEADa, a pivotal Phase 3 investigational study of icotrokinra (JNJ-2113), the first targeted oral peptide that...
- New Alzheimer's prevention trial receives $74.5 million NIH granton November 14, 2024 at 5:11 pm
PHOENIX, Nov. 14, 2024. A new Alzheimer's prevention study has received a $74.5 million five-year grant from the National Institute on Aging, part of the National Institutes of Health (NIH). The two-part study will be conducted in members of the...
- Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Diseaseon November 14, 2024 at 12:11 am
PRINCETON, N.J., Nov. 14, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...
- Researchers Uncover New Role of Mutant Proteins in Some of the Deadliest Cancerson November 12, 2024 at 7:11 pm
November 12, 2024 -- Researchers at the National Institutes of Health (NIH) and their collaborators have discovered a new way in which RAS genes, which are commonly mutated in cancer, may drive tumor growth beyond their well-known role in signaling...
- Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenibon November 12, 2024 at 7:11 pm
WALTHAM, Mass., Nov. 12, 2024 /PRNewswire/ -- Syndax Pharmaceuticals, a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced positive topline results from the relapsed or refractory (R/R)...
- Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcomaon November 12, 2024 at 6:11 pm
CHICAGO and FORT WORTH, Texas, Nov. 12, 2024 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the...
- Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndromeon November 11, 2024 at 7:11 pm
NEW YORK--(BUSINESS WIRE)--Nov. 11, 2024-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced positive interim...
- Nipocalimab is the First and Only Investigational Therapy Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Adults Living with Moderate-to-Severe Sjögren’s Diseaseon November 11, 2024 at 2:11 am
Spring House, PA (November 11, 2024) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted nipocalimab Breakthrough Therapy designation (BTD) for the treatment of adults living with...
- AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophreniaon November 11, 2024 at 2:11 am
NORTH CHICAGO, Ill., Nov. 11, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an...
- Palleon Pharmaceuticals Presents Results from the Phase 1/2 GLIMMER-01 Trial of E-602 in Combination with Cemiplimab in Patients with Solid Tumors at the Society for Immunotherapy of Cancer (SITC) Annual Meetingon November 8, 2024 at 3:11 am
WALTHAM, MA, November 8, 2024 — Palleon Pharmaceuticals, a clinical-stage company pioneering glyco-immunology drug development to treat autoimmune diseases and cancer, today announced results from the Phase 1/2 GLIMMER-01 trial of E-602, its...
- AskBio Receives FDA Rare Pediatric Disease and Orphan-Drug Designations for AB-1003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9on November 7, 2024 at 3:11 am
Research Triangle Park, N.C. – November 7, 2024 – Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that AB-1003 (also known as...
- JAMA Oncology Publishes Phase 1b/2 Study Data on IASO Bio's Equecabtagene Autoleucel (Fucaso™) in the Treatment of Relapsed/Refractory Multiple Myelomaon November 7, 2024 at 12:11 am
SHANGHAI, NANJING, and SAN JOSE, CA., November 07, 2024 – IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products...
- Leads Biolabs Receives Orphan Drug Designation from the US FDA for LBL-034, a Uniquely Designed, Highly Differentiated Anti-GPRC5D/CD3 Bispecific Antibody, for the Treatment of Multiple Myelomaon November 6, 2024 at 12:11 am
NANJING, China, Nov. 6, 2024 /PRNewswire/ -- On November 1, Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-034, a humanized bispecific T-cell engaging antibody targeting both GPRC5D and CD3 which is...
